Medmira (TSE:MIR) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals. The company received FDA approval for its HIV test and is awaiting further approvals for its Syphilis test in Canada. Additionally, MedMira has signed significant distribution agreements in the US to enhance its product reach.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.